Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
This study has been completed.
Study NCT00356889 Information provided by National Cancer Institute (NCI)
First Received on July 26, 2006. Last Updated on April 1, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Cancer
Recurrent Gallbladder Cancer
Unresectable Gallbladder Cancer
Additional conditions recognized in this trial
Bile Duct Neoplasms
Biliary Tract Neoplasms
Cholangiocarcinoma
Gallbladder Neoplasms
Gastrointestinal Neoplasms
More general conditions related to this trial
Adenocarcinoma
Bile Duct Diseases
Biliary Tract Diseases
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gallbladder Diseases
Gastrointestinal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
erlotinib hydrochloride
bevacizumab
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Erlotinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
